J. H. M. Schellens

Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study

Janice M. Mehnert, Hope S. Rugo, Bert H. O’Neil et al. · Annals of Oncology · 2017 · 57 citations · Full text

Medicine, Oncology, Pharmacology +15

Selection of oncology medicines in low- and middle-income countries

Y. T. Bazargani, A. de Boer, J. H. M. Schellens et al. · Annals of Oncology · 2013 · 41 citations

Medicine, Oncology, Oncology Pharmacy +13

Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028

Evan Alley, L Rhoda Molife, Armando Santoro et al. · Cancer Research · 2015 · 36 citations

Medicine, Oncology, Pharmacology +17

Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers

Markus Joerger, Tessa M. Bosch, Valerie D. Doodeman et al. · European Journal of Clinical Pharmacology · 2006 · 31 citations

Life Sciences, Genetics, Molecular Genetics +6

UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial

Alain Ravaud, Markus Borner, J. H. M. Schellens et al. · European Journal of Cancer · 2001 · 27 citations

Medicine, Oncology, Pharmacology +11